Biologically Focused Therapy of Treatment-Refractory MDS Patients
Trial ID or NCT#
NCT05245032
Status
NOT RECRUITING
Purpose
This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.
Official Title
Biologically Focused Therapy of Treatment Refractory MDS Patients
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
- - Provide informed consent; - Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN with >= 5% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML) 1 and 2 by WHO classification - Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating agent therapy - Cytogenetics reported
Exclusion Criteria:
- - Hypoplastic MDS - Patients without adequate marrow samples for ex vivo analysis
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Jack Taw
650-723-2781
View on ClinicalTrials.gov
